Bone Marrow Transplantation, Hematologic Neoplasms
Conditions
Interventions
L. plantarum, G18 lineage, was administrated as a probiotic to the treatment group (n= 22) at a
dose of 5 x 10e9 Colony Forming Units (CFU) twice daily in the form of gastric release capsules produce
G07.203.300.456.500
B03.353.750.450.475.612
Sponsors
Fundação de Amparo à Pesquisa do Estado de São Paulo
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Eligibility
Inclusion criteria
Inclusion criteria: the presence of oncohematological disease and indication for HSCT; being over 18 years old; not having performed previous gastrointestinal tract surgery; be colonized by antibiotic-resistant bacteria identified by a positive surveillance culture within a maximum of six months before entering the study; and agree to participate in the study after signing the informed consent form.
Exclusion criteria
Exclusion criteria: patient who has agreed to participate in the study, however, has collected fecal material after HSCT; patient with low adherence to therapy (less than 50%).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decolonization by multi-resistant bacteria; Evaluation through the culture of rectal or perianal swab surveillance of participants, previously collected the intervention and weekly during the transplant | — |
Secondary
| Measure | Time frame |
|---|---|
| modulation of the intestinal microbiome; Evaluated through the analysis of intestinal microbiome of stool samples collected weekly (the first before the intervention) until the transplant graft.;Reduction of HSCT infection; assessed by comparing the groups, intervention and control, of infections that occurred during HSCT (medical note). | — |
Countries
Brazil
Contacts
Public ContactBruna Moraes
Outcome results
None listed